Brought to you by 
Series A brings in $12.6mm for Rheonix
22 Apr 2010
Executive Summary
Rheonix Inc. (developing point-of-care tests for infectious diseases) has closed its Series A financing, raising $12.6mm from a group of regional and international firms led by the Cayuga Venture Fund and individual investors. The funds will support ongoing development of the company's CARD (Chemistry And Reagent Device) platform that incorporates high-throughput molecular diagnostics into a single system.
Deal Industry
- In Vitro Diagnostics
- Medical Devices
- Research, Analytical Equipment & Supplies
-
In Vitro Diagnostics
- Biosensors
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Nanotechnology, Chips, etc.
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series A brings in $12.6mm for Rheonix
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice